Bank of America
: UP to buy from hold at ING Barings; price target: 70.
: DOWN to hold from buy at ING Barings.
: RESTARTED strong buy at
Morgan Stanley Dean Witter
: NEW buy at
, price target: 70.
: NEW buy at
: NEW buy at ABN Amro.
: NEW accumulate/buy at
: 2001 revenue estimates DOWN to $14.3 million from $20.5 million and 2001 EPS estimate lowered at
ING Barings commented on e-brokerage firms:
- E*Trade (EGRP) : DOWN to hold from buy.
Charles Schwab (SCH) : second-quarter EPS view DOWN to 22 cents from 25 cents and full-year 2000 EPS estimate to 98 cents from $1.11.
Knight/Trimark (NITE) : price target DOWN to 47 from 65.
Merrill Lynch analyst Todd Nelson initiated coverage of the genomics and life science tools and technologies sector:
- Invitrogen (IVGN) : at intermediate-term buy and long-term buy; price target: 63.
Techne (TECH) - Get Report at intermediate-term accumulate and long-term buy; price target: 87 1/2.
Celera Genomics (CRA) at intermediate-and long-term accumulate .
GeneLogic (GLGC) at intermediate-term neutral and long-term accumulate.
PE Biosystems (PEB) - Get Report at intermediate- and long-term buy; price target: 70.
CuraGen (CRGN) at intermediate-term accumulate and long-term buy.
Incyte Genomics (INCY) - Get Report at intermediate-term accumulate and long-term buy; price target: 75.